Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00776555 · ClinicalTrials.gov registry record · Phase 1
Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution
A Phase 1 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00776555: Clinical Trial Phase 1 study, sponsored by Shire.
NCT00776555 is a Phase 1 study that was terminated before completion, run by Shire. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00776555, a Phase 1 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution. Hypothesis: DRQ-S, question 2 will show no difference between the two drugs
Primary Outcome
Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.
Interventions
- DRUG Lisdexamfetamine Dimesylate
- DRUG Racemic mixture of dextroamphetamine and lisdexamfetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-11-21 |
| Est. Completion | 2009-03-31 |
| Phase | Phase 1 |
Why NCT00776555 stopped before completion
NCT00776555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Lisdexamfetamine Dimesylate is the first listed.
NCT00776555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00776555 about?
NCT00776555 is a clinical study titled "Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution". The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution. Hypothesis: DRQ-S, question 2 will show no difference between the two drug...
What is the current status of trial NCT00776555?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-11-21. Estimated completion is 2009-03-31.
What interventions are being tested in trial NCT00776555?
The interventions under investigation include: Lisdexamfetamine Dimesylate (DRUG), Racemic mixture of dextroamphetamine and lisdexamfetamine (DRUG).
Who is sponsoring clinical trial NCT00776555?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00776555's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI